Project

Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Ongoing - recruitment closed · 2021 until 2026

Weindler Susanne, Berbic Hong Phuong, Frehner Jan